Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006033 · ClinicalTrials.gov registry record · Phase 2
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006033: Completed Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00006033 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006033, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Inserting the gene for interleukin-2 into head and neck cancer cells may make the body build an immune response to kill the tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether the interleukin-2 gene is more effective than methotrexate for advanced head and neck cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of the interleukin-2 gene with that of methotrexate in treating patients who have recurrent or refractory stage III or stage IV head and neck cancer.
Interventions
- DRUG methotrexate
- BIOLOGICAL gene therapy
- BIOLOGICAL interleukin-2 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
What the finished NCT00006033 record still lists
NCT00006033 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which methotrexate is the first listed.
NCT00006033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006033 about?
NCT00006033 is a clinical study titled "Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer". RATIONALE: Inserting the gene for interleukin-2 into head and neck cancer cells may make the body build an immune response to kill the tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether the interleukin...
What is the current status of trial NCT00006033?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00006033?
The interventions under investigation include: methotrexate (DRUG), gene therapy (BIOLOGICAL), interleukin-2 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006033?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia